11 citations
,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
Spironolactone may be a better acne treatment for adult women than antibiotics.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
1 citations
,
November 2020 in “Journal of The American Academy of Dermatology” GSK-36 downregulation with UTMD improves plaque stability in atherosclerosis treatment.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
11 citations
,
March 2014 in “Journal of The European Academy of Dermatology and Venereology” Hair loss gene linked to prostate issues.
November 2023 in “Open Repository of the University of Porto (University of Porto)” Community pharmacies and pharmacists play a crucial role in improving community health.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
6 citations
,
May 2021 in “Clinical Chemistry and Laboratory Medicine” Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
1 citations
,
January 2010 in “uO Research (University of Ottawa)” Atrazine and finasteride disrupt hormone signaling and affect frog development.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
October 2025 in “Journal of the Endocrine Society” Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.